What’s Propelling Biospecifics Tech Corporation (NASDAQ:BSTC) After Higher Shorts Reported?

September 17, 2017 - By Marguerite Chambers

 What’s Propelling Biospecifics Tech Corporation (NASDAQ:BSTC) After Higher Shorts Reported?

Investors sentiment decreased to 1.26 in Q4 2016. Its down 0.16, from 1.42 in 2016Q3. It fall, as 8 investors sold BioSpecifics Technologies Corp. shares while 31 reduced holdings. 16 funds opened positions while 33 raised stakes. 3.87 million shares or 3.17% more from 3.75 million shares in 2016Q3 were reported.
Moreover, Strs Ohio has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 4,700 shares. Rice Hall James Lc holds 0.37% or 132,015 shares. First Quadrant Ltd Partnership Ca has invested 0.04% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Renaissance Technologies Ltd Co holds 0.03% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 332,746 shares. State Bank Of New York Mellon Corp, New York-based fund reported 67,418 shares. Clarivest Asset Mngmt Ltd Limited Liability Company reported 0.02% stake. Cadence Limited Liability Corporation stated it has 0.08% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Rhumbline Advisers has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Blackrock Grp reported 4,250 shares stake. Acadian Asset Mngmt Llc holds 0.05% or 191,127 shares in its portfolio. Gsa Capital Prns Limited Liability Partnership has 0.14% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Prudential has invested 0.01% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Blackrock Incorporated has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). National Bank & Trust Of America De accumulated 1,118 shares. Elk Creek Ltd Limited Liability Company reported 0.55% in BioSpecifics Technologies Corp. (NASDAQ:BSTC).

The stock of Biospecifics Tech Corporation (NASDAQ:BSTC) registered an increase of 6.56% in short interest. BSTC’s total short interest was 139,700 shares in September as published by FINRA. Its up 6.56% from 131,100 shares, reported previously. With 21,600 shares average volume, it will take short sellers 7 days to cover their BSTC’s short positions. The short interest to Biospecifics Tech Corporation’s float is 3.27%.

The stock decreased 1.90% or $0.91 on September 15, reaching $47.1. About 70,484 shares traded or 176.79% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 49.91% since September 17, 2016 and is uptrending. It has outperformed by 33.21% the S&P500.

BioSpecifics Technologies Corp. is a biopharmaceutical firm involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The company has market cap of $337.44 million. The Firm has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability firm , an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. It has a 28.77 P/E ratio. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe).

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Ratings Coverage

Among 2 analysts covering BioSpecifics Technologies Corp (NASDAQ:BSTC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioSpecifics Technologies Corp had 2 analyst reports since March 8, 2016 according to SRatingsIntel. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) has “Buy” rating given on Thursday, August 10 by H.C. Wainwright. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) earned “Buy” rating by Rodman & Renshaw on Tuesday, March 8.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Prnewswire.com which released: “BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results” on May 10, 2017, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2014 …” published on March 13, 2015, Seekingalpha.com published: “Biospecifics Technology Corp.: Underfollowed And Undervalued” on April 21, 2016. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Marketwatch.com and their article: “47.10” published on January 31, 2011 as well as Prnewswire.com‘s news article titled: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of …” with publication date: November 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: